JP2022511951A - Ｐｅｇ化された成長ホルモンアンタゴニスト - Google Patents

Ｐｅｇ化された成長ホルモンアンタゴニスト Download PDF

Info

Publication number
JP2022511951A
JP2022511951A JP2021533244A JP2021533244A JP2022511951A JP 2022511951 A JP2022511951 A JP 2022511951A JP 2021533244 A JP2021533244 A JP 2021533244A JP 2021533244 A JP2021533244 A JP 2021533244A JP 2022511951 A JP2022511951 A JP 2022511951A
Authority
JP
Japan
Prior art keywords
growth hormone
human growth
receptor antagonist
hormone receptor
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021533244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511951A5 (https=
Inventor
ブロディ、リチャード、エス．
Original Assignee
モレキュラー テクノロジーズ ラボラトリーズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/216,230 external-priority patent/US10874717B2/en
Application filed by モレキュラー テクノロジーズ ラボラトリーズ エルエルシー filed Critical モレキュラー テクノロジーズ ラボラトリーズ エルエルシー
Publication of JP2022511951A publication Critical patent/JP2022511951A/ja
Publication of JP2022511951A5 publication Critical patent/JP2022511951A5/ja
Priority to JP2024195736A priority Critical patent/JP2025026898A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021533244A 2018-12-11 2019-12-10 Ｐｅｇ化された成長ホルモンアンタゴニスト Pending JP2022511951A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024195736A JP2025026898A (ja) 2018-12-11 2024-11-08 Ｐｅｇ化された成長ホルモンアンタゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/216,230 US10874717B2 (en) 2015-07-07 2018-12-11 Pegylated growth hormone antagonists
US16/216,230 2018-12-11
PCT/US2019/065385 WO2020123450A1 (en) 2018-12-11 2019-12-10 Pegylated growth hormone antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024195736A Division JP2025026898A (ja) 2018-12-11 2024-11-08 Ｐｅｇ化された成長ホルモンアンタゴニスト

Publications (2)

Publication Number Publication Date
JP2022511951A true JP2022511951A (ja) 2022-02-01
JP2022511951A5 JP2022511951A5 (https=) 2022-12-16

Family

ID=71076634

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533244A Pending JP2022511951A (ja) 2018-12-11 2019-12-10 Ｐｅｇ化された成長ホルモンアンタゴニスト
JP2024195736A Pending JP2025026898A (ja) 2018-12-11 2024-11-08 Ｐｅｇ化された成長ホルモンアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024195736A Pending JP2025026898A (ja) 2018-12-11 2024-11-08 Ｐｅｇ化された成長ホルモンアンタゴニスト

Country Status (4)

Country Link
EP (1) EP3893919A4 (https=)
JP (2) JP2022511951A (https=)
CA (1) CA3121241A1 (https=)
WO (1) WO2020123450A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250101076A1 (en) * 2023-09-22 2025-03-27 Molecular Technologies Laboratories Llc Growth hormone receptor antagonists exhibiting increased receptor binding properties and increased serum half-life

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170007711A1 (en) * 2015-07-07 2017-01-12 Richard S. Brody Pegylated growth hormone antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
BRPI0519430A2 (pt) * 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
US10874717B2 (en) 2015-07-07 2020-12-29 Burr Oak Therapeutics LLC Pegylated growth hormone antagonists
WO2019211842A1 (en) 2018-04-30 2019-11-07 Opko Biologics Ltd. Long-acting human growth hormone-antagonists and methods of producing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170007711A1 (en) * 2015-07-07 2017-01-12 Richard S. Brody Pegylated growth hormone antagonists

Also Published As

Publication number Publication date
WO2020123450A1 (en) 2020-06-18
EP3893919A4 (en) 2022-11-30
JP2025026898A (ja) 2025-02-26
EP3893919A1 (en) 2021-10-20
CA3121241A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
US11578427B2 (en) Designed ankyrin repeat domains with altered surface residues
US10874717B2 (en) Pegylated growth hormone antagonists
US20170007711A1 (en) Pegylated growth hormone antagonists
JP6023703B2 (ja) 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
US8642545B2 (en) Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof
CN102234310B (zh) 一种聚乙二醇修饰蛋白的分离纯化方法
TW201323442A (zh) 低密度脂蛋白相關蛋白６（ｌｒｐ６）－半衰期延長構築體
CN113840831A (zh) 医用ngf拮抗剂
CN107207623A (zh) Fc融合高亲和力IgE受体α链
US20220119448A1 (en) Artificial recombinant protein for improving performance of active protein or polypeptide and use thereof
CN106488930B (zh) 新型多肽
JP2022502467A (ja) オリゴマー伸長インスリン−ｆｃコンジュゲートおよびそれらの医学的使用
JP2025026898A (ja) Ｐｅｇ化された成長ホルモンアンタゴニスト
JP2024016080A (ja) Ｐｅｇ化された成長ホルモンアンタゴニストの治療薬
JP4237703B2 (ja) インスリン様成長因子結合タンパク質−４及びポリ（エチレングリコール）の接合体
BR112022000760B1 (pt) Composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração
US20100249029A1 (en) Peptides with high affinity for the prolactin receptor
CN103087182B (zh) 一种定点修饰n-末端的聚乙二醇化生长激素拮抗剂及其制备方法
US20250101076A1 (en) Growth hormone receptor antagonists exhibiting increased receptor binding properties and increased serum half-life
EP4661892A1 (en) Tnf-alpha binding agents and methods of using the same
WO2024137820A1 (en) Insulin receptor antagonist
CN105367629B (zh) 一种促红细胞生成素模拟肽以及其制备方法和用途
HK1244016B (zh) FC融合高亲和力IGE受体α链

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240503

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240723